Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Recombinant Meningococcal Group B Vaccine (E. Coli) Phase I Study
NCT06314880Phase 1Recruiting
- Sponsor
- Zhifei Green Bamboo
- Start
- Jul 2023
- Primary completion
- Dec 2024
- Modality
- Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of recombinant meningococcal group b vaccine in meningococcal group B infection (MenB) (5 arms), sponsored by Zhifei Green Bamboo. Primary endpoints: Incidence rate of all Adverse Events, Incidence rate of solicited Adverse Events (Immediate) at 30 minutes and 3 more. Started Jul 2023; status: recruiting.
02
Drugs
recombinant meningococcal group b vaccine
03
Conditions
meningococcal group B infection (MenB)
Beyond the preview
Go deeper on NCT06314880.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06314880.